SidaGhanaV1, PascalFrancis, Curation, bibRecord, 000069

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Identifieur interne : 000069 ( PascalFrancis/Curation ); précédent : 000068; suivant : 000070

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Auteurs : Jérome Legoff [France] ; Philippe Mayaud [Royaume-Uni] ; Gérard Gresenguet [Afrique du Sud] ; Helen A. Weiss [Royaume-Uni] ; Khonde Nzambi [Ghana] ; Eric Frost [Canada] ; Jacques Pepin [Canada] ; Laurent Belec [France]

Source :

Journal of clinical microbiology : (Print) [ 0095-1137 ] ; 2008.

RBID : Pascal:08-0307437

Descripteurs français

Pascal (Inist)
- Herpesvirus hominis 2, Détection, Anticorps, Microbiologie.

English descriptors

KwdEn :
- Antibody, Detection, Human herpesvirus 2, Microbiology.

Abstract

The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes simplex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus (HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2 ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434 women were tested with the HerpeSelect assay, and a subsample (n = 199) was tested by the Kalon assay. Ulcer swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital (lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection, 71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day 14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical history.

A01	`01`	`1`		`@0 0095-1137`
A02	`01`			`@0 JCMIDW`
A03		`1`		`@0 J. clin. microbiol. : (Print)`
A05				`@2 46`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2`
A11	`01`	`1`		`@1 LEGOFF (Jérome)`
A11	`02`	`1`		`@1 MAYAUD (Philippe)`
A11	`03`	`1`		`@1 GRESENGUET (Gérard)`
A11	`04`	`1`		`@1 WEISS (Helen A.)`
A11	`05`	`1`		`@1 NZAMBI (Khonde)`
A11	`06`	`1`		`@1 FROST (Eric)`
A11	`07`	`1`		`@1 PEPIN (Jacques)`
A11	`08`	`1`		`@1 BELEC (Laurent)`
A14	`01`			`@1 Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou @2 Paris @3 FRA @Z 1 aut. @Z 8 aut.`
A14	`02`			`@1 Laboratoire de Microbiologie, Hôpital Saint-Louis @2 Paris @3 FRA @Z 1 aut.`
A14	`03`			`@1 Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine @2 London @3 GBR @Z 2 aut. @Z 4 aut.`
A14	`04`			`@1 Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine @2 London @3 GBR @Z 2 aut. @Z 4 aut.`
A14	`05`			`@1 Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'lntervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé @2 Bangui @3 ZAF @Z 3 aut.`
A14	`06`			`@1 West African Project To Combat AIDS and STDs @2 Accra @3 GHA @Z 5 aut.`
A14	`07`			`@1 Centre for International Health, University of Sherbrooke @2 Sherbrooke @3 CAN @Z 6 aut. @Z 7 aut.`
A17	`01`	`1`		`@1 ANRS 12-12 Study Group @3 INC`
A20				`@1 1914-1918`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 17088 @5 354000197845200040`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 16 ref.`
A47	`01`	`1`		`@0 08-0307437`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of clinical microbiology : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes simplex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus (HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2 ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434 women were tested with the HerpeSelect assay, and a subsample (n = 199) was tested by the Kalon assay. Ulcer swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital (lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection, 71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day 14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical history.
C02	`01`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Herpesvirus hominis 2 @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Human herpesvirus 2 @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Herpesvirus hominis 2 @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Détection @5 05`
C03	`02`	`X`	`ENG`	`@0 Detection @5 05`
C03	`02`	`X`	`SPA`	`@0 Detección @5 05`
C03	`03`	`X`	`FRE`	`@0 Anticorps @5 06`
C03	`03`	`X`	`ENG`	`@0 Antibody @5 06`
C03	`03`	`X`	`SPA`	`@0 Anticuerpo @5 06`
C03	`04`	`X`	`FRE`	`@0 Microbiologie @5 07`
C03	`04`	`X`	`ENG`	`@0 Microbiology @5 07`
C03	`04`	`X`	`SPA`	`@0 Microbiología @5 07`
C07	`01`	`X`	`FRE`	`@0 Alphaherpesvirinae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Alphaherpesvirinae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Alphaherpesvirinae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Herpesviridae @2 NW`
C07	`02`	`X`	`ENG`	`@0 Herpesviridae @2 NW`
C07	`02`	`X`	`SPA`	`@0 Herpesviridae @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
N21				`@1 196`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000071

Links to Exploration step

Pascal:08-0307437

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2</title>
<author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérome" last="Legoff">Jérome Legoff</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratoire de Microbiologie, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'lntervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1>
<s2>Bangui</s2>
<s3>ZAF</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Afrique du Sud</country>
</affiliation>
</author>
<author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>West African Project To Combat AIDS and STDs</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0307437</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0307437 INIST</idno>
<idno type="RBID">Pascal:08-0307437</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000071</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000069</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2</title>
<author><name sortKey="Legoff, Jerome" sort="Legoff, Jerome" uniqKey="Legoff J" first="Jérome" last="Legoff">Jérome Legoff</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Laboratoire de Microbiologie, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mayaud, Philippe" sort="Mayaud, Philippe" uniqKey="Mayaud P" first="Philippe" last="Mayaud">Philippe Mayaud</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Gresenguet, Gerard" sort="Gresenguet, Gerard" uniqKey="Gresenguet G" first="Gérard" last="Gresenguet">Gérard Gresenguet</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'lntervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1>
<s2>Bangui</s2>
<s3>ZAF</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Afrique du Sud</country>
</affiliation>
</author>
<author><name sortKey="Weiss, Helen A" sort="Weiss, Helen A" uniqKey="Weiss H" first="Helen A." last="Weiss">Helen A. Weiss</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Nzambi, Khonde" sort="Nzambi, Khonde" uniqKey="Nzambi K" first="Khonde" last="Nzambi">Khonde Nzambi</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>West African Project To Combat AIDS and STDs</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Ghana</country>
</affiliation>
</author>
<author><name sortKey="Frost, Eric" sort="Frost, Eric" uniqKey="Frost E" first="Eric" last="Frost">Eric Frost</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Pepin, Jacques" sort="Pepin, Jacques" uniqKey="Pepin J" first="Jacques" last="Pepin">Jacques Pepin</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Belec, Laurent" sort="Belec, Laurent" uniqKey="Belec L" first="Laurent" last="Belec">Laurent Belec</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical microbiology : (Print)</title>
<title level="j" type="abbreviated">J. clin. microbiol. : (Print)</title>
<idno type="ISSN">0095-1137</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical microbiology : (Print)</title>
<title level="j" type="abbreviated">J. clin. microbiol. : (Print)</title>
<idno type="ISSN">0095-1137</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term>
<term>Detection</term>
<term>Human herpesvirus 2</term>
<term>Microbiology</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Herpesvirus hominis 2</term>
<term>Détection</term>
<term>Anticorps</term>
<term>Microbiologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes simplex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus (HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2 ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434 women were tested with the HerpeSelect assay, and a subsample (n = 199) was tested by the Kalon assay. Ulcer swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital (lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection, 71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day 14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical history.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0095-1137</s0>
</fA01>
<fA02 i1="01"><s0>JCMIDW</s0>
</fA02>
<fA03 i2="1"><s0>J. clin. microbiol. : (Print)</s0>
</fA03>
<fA05><s2>46</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEGOFF (Jérome)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MAYAUD (Philippe)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GRESENGUET (Gérard)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>WEISS (Helen A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>NZAMBI (Khonde)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FROST (Eric)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>PEPIN (Jacques)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BELEC (Laurent)</s1>
</fA11>
<fA14 i1="01"><s1>Université Paris Descartes, Equipe Immunité et Biothérapie Muqueuse, Unité INSERM Internationale U743 (Immunologie Humaine), Centres de Recherches Biomédicales des Cordeliers and Laboratoire de Virologie, Hôpital Européen Georges Pompidou</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Laboratoire de Microbiologie, Hôpital Saint-Louis</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Clinical Research Unit, Department of Infectious and Tropical Diseases, and Infectious Diseases Epidemiology Unit, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Centre National de Référence des Maladies Sexuellement Transmissibles et du SIDA de Bangui and Unité de Recherches et d'lntervention sur les Maladies Sexuellement Transmissibles et du SIDA, Faculté des Sciences de la Santé</s1>
<s2>Bangui</s2>
<s3>ZAF</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>West African Project To Combat AIDS and STDs</s1>
<s2>Accra</s2>
<s3>GHA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Centre for International Health, University of Sherbrooke</s1>
<s2>Sherbrooke</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>ANRS 12-12 Study Group</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>1914-1918</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>17088</s2>
<s5>354000197845200040</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>16 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0307437</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical microbiology : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The performances of commercial enzyme-linked immunosorbent assays (ELISAs) in detecting herpes simplex virus type 2 (HSV-2) antibodies have been inconsistent for African and human immunodeficiency virus (HIV)-positive populations. We compared the performances of the HerpeSelect and Kalon glycoprotein G2 ELISAs for patients with genital ulcer disease in Ghana and the Central African Republic. Sera from 434 women were tested with the HerpeSelect assay, and a subsample (n = 199) was tested by the Kalon assay. Ulcer swabs and cervicovaginal lavage samples were tested for HSV-2 DNA by PCR. HSV-2-seronegative women with detectable genital HSV-2 DNA were retested for HSV-2 antibodies 14 and 28 days later by the two ELISAs. A total of 346 (80%) women were positive by HerpeSelect at baseline, and 225 (54%) had detectable genital (lesional or cervicovaginal) HSV-2 DNA. Sixty-six (19%) HerpeSelect-positive samples had low-positive index values (1.1 to 3.5), and 58% of these samples had detectable genital HSV-2 DNA. Global agreement between the two serological assays was 86%. Concordance was high (99%) for sera that were negative by HerpeSelect or had high index values (>3.5). Defining infection detected by HSV-2 DNA PCR and/or Kalon assay as true infection, 71% of sera with low-positive index values were associated with true HSV-2 infection. Twenty-five women were identified as having nonprimary first-episode genital HSV-2 infection. Rates of HSV-2 seroconversion at day 14 were 77% (10/13 patients) by HerpeSelect assay and 23% (3/13 patients) by Kalon assay, with four additional seroconversions detected by Kalon assay at day 28. HIV serostatus did not influence assay performance. Low index values obtained with the HerpeSelect assay may correspond to true HSV-2 infection, in particular to nonprimary first episodes of genital HSV-2 infection, and need to be interpreted in the context of clinical history.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Herpesvirus hominis 2</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Human herpesvirus 2</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Herpesvirus hominis 2</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Détection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Detection</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Detección</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Anticorps</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Antibody</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Anticuerpo</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Microbiologie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Microbiology</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Microbiología</s0>
<s5>07</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Alphaherpesvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Alphaherpesvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Alphaherpesvirinae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Herpesviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Herpesviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Herpesviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fN21><s1>196</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000069 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000069 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    SidaGhanaV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:08-0307437
   |texte=   Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2
}}

This area was generated with Dilib version V0.6.31.
Data generation: Tue Nov 7 18:07:38 2017. Site generation: Tue Mar 5 15:01:57 2024

	Le SIDA au Ghana (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Le SIDA au Ghana (serveur d'exploration)

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri